·   Log in

Teva seeks to market generic version of Nuvigil

Written by: David Castillo on October 24th, 2009
Bookmark and Share
Nuvigil_50_150_250_57890_57891
Teva seeks to market generic version of Nuvigil   | read this item

Last Wednesday, Cephalon Inc. notified Teva Pharmaceuticals has filed an application to the United States (US) Food and Drug Administration to seek approval to market Nuvigil.

Nuvigil is a sleep disorder drug, which can improve obstructive sleep apnea. It is actually an improved version of Cephalon’s Provigil, another sleep disorder drug.

In its application, Teva Pharmaceuticals says that Cephalon patents for Nuvigil are “invalid invalid, unenforceable and/or will not be infringed by the product described in Teva’s submission.”

According to reports, the company is now reviewing the notice letter.

Source: Philadelphia Business Journal

Nuvigil_50_150_250_57890_57891


  1. [...] Read the original here: Teva seeks to market generic version of Nuvigil | Shift Work … [...]

You must be logged in to post a comment.

Latest Headlines

In The News

Singapore Sleep Society launches sleep disorder awareness campaign thumbnail

Singapore Sleep Society launches sleep disorder awareness campaign

The Singapore Sleep Society will be
Sleep apnea in relation to cardiovascular problems thumbnail

Sleep apnea in relation to cardiovascular problems

Experts claim that obstructive sleep apnea
Free Sleep Disorder Screening Clinic at Sound Sleep Centers Coming to Burnsville thumbnail

Free Sleep Disorder Screening Clinic at Sound Sleep Centers Coming to Burnsville

[PR-USA.net] — Snoring and Sleep disorders
What Do Sleep, Diabetes and Red Have in Common with Heart Disease? thumbnail

What Do Sleep, Diabetes and Red Have in Common with Heart Disease?

[NewsWise] — OSA: The Sleep Disorder
Dr. Oz Show Focuses on Patients with Sleep Disorders Spotlight on 20 Million Americans with Sleep Apnea thumbnail

Dr. Oz Show Focuses on Patients with Sleep Disorders Spotlight on 20 Million Americans with Sleep Apnea

[Business Wire] — Watermark Medical CEO